Evidence map›Paper›PMID 41757946›Full record

ArticleMicrobiology spectrum2026

A mutation-aware proteomics approach for designing a multi-epitope vaccine against multidrug-resistant

Gul Afshan, Namrah Yaseen, Asad U Khan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gul Afshan *Antimicrobial Resistance Lab, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Namrah Yaseen *Antimicrobial Resistance Lab, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Asad U KhanAntimicrobial Resistance Lab, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.ORCID 0000-0001-9191-9423

Funding

Department of Biotechnology, Ministry of Science and Technology, India BT/PR40148/BTIS/137/20/2021
6 · The paper itself

Abstract

The increasing prevalence of multidrug-resistant IMPORTANCE: Multidrug resistance has become a common phenomenon leading to difficulty in infection control. No options are left to treat such infections after the emergence of colistin resistance. Therefore, this approach to developing multi-epitope therapeutic vaccines is very promising to face the challenge of infection control. This study is based on comparative pan-genomic and subtractive proteomic analyses of 30 proteomes, which provide a wider range of proteins to select multiple epitopes for effective vaccine.

Indexed as

Acinetobacter baumanniiBacterial VaccinesEpitopesPseudomonas aeruginosaAcinetobacter InfectionsDrug Resistance, Multiple, BacterialEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMutationProtein Subunit VaccinesProteomicsPseudomonas InfectionsBacterial VaccinesEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteProtein Subunit Vaccinesantimicrobial resistancebacterial pan-genome analysisextensively drug resistantmultidrug resistancevaccine

Identifiers

PMID41757946
PMCPMC13055230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.